Ranatuerin-2Lb

General Information


DRACP ID  DRACP00257

Peptide Name   Ranatuerin-2Lb

Sequence  GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC

Sequence Length  32

UniProt ID  Not available

PubChem CID  Not available

Origin  Rana luteiventris; Rana pretiosa

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
A549 Lung adenocarcinoma Carcinoma IC50=15.32 µM MTT assay 24h 1
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=45.25 µM MTT assay 24h 1
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=37.23 µM MTT assay 24h 1
LoVo Colon adenocarcinoma Carcinoma IC50=59.78 µM MTT assay 24h 1

Hemolytic Activity  Human erythrocytes: 50% Hemolysis>100 µM; Sheep erythrocytes: <10% Hemolysis=256 µM

Normal (non-cancerous) Cytotoxicity  HEK293T: IC50=63.16 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00257

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys27<--->Cys32

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C140H251N39O41S2

Absent amino acids  EFHMPRWY

Common amino acids  K

Mass  375406

Pl  10.23

Basic residues  5

Acidic residues  1

Hydrophobic residues  14

Net charge  4

Boman Index  -47

Hydrophobicity  59.06

Aliphatic Index  125

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  125

Absorbance 280nm  4.03

Polar residues  11

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 34073203

Title  Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides

Doi 10.3390/ijms22115630

Year  2021

Literature 2

Pubmed ID 21295070

Title  Host defense peptides in skin secretions of the Oregon spotted frog Rana pretiosa: implications for species resistance to chytridiomycosis

Doi 10.1016/j.dci.2011.01.017

Year  2011

Patent

Patent ID CN113855783A

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.